Navigation Links
Profectus Biosciences to Present at Key Investor Conference in January 2010
Date:1/8/2010

Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates to treat chronic viral infections, announced today that the company will present at the upcoming Biotech Showcase investor conference and will be attending the J.P. Morgan Healthcare Conference in San Francisco.

Baltimore, MD (Vocus) January 6, 2010 -- Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates to treat chronic viral infections, announced today that the company will present at the upcoming Biotech Showcase investor conference and will be attending the J.P. Morgan Healthcare Conference in San Francisco. These conferences will provide strategic investment and partnering opportunities for Profectus, whose novel ProfectusVAX™ prime/boost vaccines and NF-kB small molecule programs continue to progress on the cutting edge of research and development.

Dr. John Eldridge, Chief Scientific Officer of Profectus BioSciences, commented, “It is an exciting time for vaccine development. Recent clinical data have validated both prime/boost vaccination and the use of therapeutic vaccines to treat chronic viral infections. The Profectus vaccine program has made excellent progress over the past year and will be initiating three proof-of-concept clinical trials in collaboration with the National Institutes of Health (NIH) in 2010. In addition, we have generated very positive preclinical results in our NF-kB small molecule program. We look forward to sharing these successful corporate and R&D results at these conferences, and reaching our clinical milestones in 2010.”

2010 Biotech Showcase, January 12-13, 2010, San Francisco, CA
Oral Presentation:
Who: Dr. John Eldridge
Title: Chief Scientific Officer
When: Wednesday, January 13, 9:40 AM
Where: Heritage Room, 10th Floor, Marines’ Memorial Club & Hotel
Website: www.biotechshowcase.com

About Profectus BioSciences Inc.
Profectus Biosciences is an innovative R&D clinical-stage vaccine company devoted to advancing the treatment and prevention of chronic viral diseases. ProfectusVAX™, the Profectus proprietary vaccine approach combines its plasmid (p) DNA and rVSV (recombinant Vesicular Stomatitis Virus) vector platforms in a unique prime-boost strategy to enhance immune responses to viruses that cause chronic disease. Profectus has a pipeline of proprietary vaccine products to address diseases caused by Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Human Papilloma Virus (HPV), and Herpes Simplex Virus (HSV) as well as for Malaria. The first of three proof-of-concept clinical trials with the prime/boost HIV vaccine candidate is planned for H1 of 2010, followed by a therapeutic HCV vaccine.

The Profectus portfolio has secured over $100M in non-dilutive funding of its programs from multiple sources including the National Institutes of Health (NIH) and $19M in private equity financing, including Cross Atlantic Capital Partners (XACP). Profectus deploys these financial resources in support of its proprietary prime-boost vaccines for multiple indications. In addition, the Company is funding its early research small molecule program for potential partners. For more information, please visit: http://www.profectusbiosciences.com.

Contact:
Lisa Rivero
LaVoie Group
978-745-4200 x106
http://www.lavoiegroup.com

###

Read the full story at http://www.prweb.com/releases/biopharmaceutical/profectus_conference/prweb3413824.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record
2. Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines
3. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
4. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
5. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
6. Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone
7. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
8. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
9. YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT
10. YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
11. Cell Biosciences Acquires Protein Forest
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Profectus Biosciences to Present at Key Investor Conference in January 2010
(Date:12/8/2016)... CARDIFF, UK (PRWEB) , ... December 08, 2016 ... ... high precision light to control cells — optogenetics — is key to exciting ... state of the art, spatially patterned light projected via free-space optics stimulates small, ...
(Date:12/8/2016)... , December 8, 2016 ... expanded its customisable SureSeq™ NGS panel range with the launch ... fast and cost-effective study of variants in familial hypercholesterolemia (FH). ... variation (CNV) detection on a single small panel and allows ... content. This includes all exons for LDLR , ...
(Date:12/8/2016)... Frederick, Maryland (PRWEB) , ... ... ... Inc announces the commercial launch of flexible packaging for their exceptionally ... (“SU”) disposable bag system extends RoosterBio’s portfolio of bioprocess media products engineered ...
(Date:12/8/2016)...  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... and commercializing products to treat rare diseases where ... the long-term follow-up data from its Phase 2 ... Defense Regulator (IDR), in the treatment of oral ... undergoing chemoradiation therapy (CRT).  The additional 12-month safety ...
Breaking Biology Technology:
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory ... experience and security for consumer electronics, and ... financial and retail industry, today announced a global ... convenient way to authenticate users of mobile banking ... TrulySecure™ software which requires no specialized ...
(Date:11/15/2016)... Research and Markets has announced the addition of the ... their offering. ... The global bioinformatics market ... 6.21 Billion in 2016, growing at a CAGR of 21.1% during ... is driven by the growing demand for nucleic acid and protein ...
Breaking Biology News(10 mins):